Literature DB >> 10662880

Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's articular index.

F Salaffi1, M Peroni, G F Ferraccioli.   

Abstract

OBJECTIVE: To compare the discriminating ability of the chronic arthritis systemic index (CASI), an index that uses the Health Assessment Questionnaire (HAQ) as the main variable, with the disease activity score (DAS) and Thompson's articular index (TAI) to detect high and low disease activity in rheumatoid arthritis (RA).
METHODS: Two hundred and two RA patients were examined. According to criteria proposed previously, they were divided into two subgroups: those with active disease and those with low activity. The areas under receiver operating characteristic (ROC) curves were employed to assess the diagnostic accuracy of the CASI in comparison with the DAS and TAI for the discrimination of disease activity.
RESULTS: The difference between areas under the ROC curves of the CASI and TAI (0. 897+/-0.023 vs 0.780+/-0.032) and between the DAS and TAI (0.933+/-0. 018 vs 0.780+/-0.032) was highly significant (P=0.0001), thus reflecting the accuracy of the diagnostic assessment. No difference arose between areas under the ROC curves of the CASI and the DAS (difference between areas=0.036+/-0.022; P=0.103).
CONCLUSION: The CASI discriminates just as well between high and low disease activity as does the DAS. Either index consisting of more than one variable performs better than TAI. We conclude that even including the HAQ, a severity parameter in the long term, it is possible to construct an index that, at any time point, evaluates disease activity as well.

Entities:  

Mesh:

Year:  2000        PMID: 10662880     DOI: 10.1093/rheumatology/39.1.90

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

Review 1.  Sulfasalazine: a review of its use in the management of rheumatoid arthritis.

Authors:  Greg L Plosker; Katherine F Croom
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Sjögren syndrome: A case report.

Authors:  C Dellafiore; A Villa; F Zibera
Journal:  J Ultrasound       Date:  2012-03-28

Review 3.  Yoga for arthritis: a scoping review.

Authors:  Steffany Haaz; Susan J Bartlett
Journal:  Rheum Dis Clin North Am       Date:  2010-12-03       Impact factor: 2.670

4.  DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

Authors:  Bert Vander Cruyssen; Stijn Van Looy; Bart Wyns; Rene Westhovens; Patrick Durez; Filip Van den Bosch; Eric M Veys; Herman Mielants; Luc De Clerck; Anne Peretz; Michel Malaise; Leon Verbruggen; Nathan Vastesaeger; Anja Geldhof; Luc Boullart; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2005-07-08       Impact factor: 5.156

5.  DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis.

Authors:  Piet L C M van Riel; Jaap Fransen
Journal:  Arthritis Res Ther       Date:  2005-08-22       Impact factor: 5.156

6.  Energy Metabolism Disorder as a Contributing Factor of Rheumatoid Arthritis: A Comparative Proteomic and Metabolomic Study.

Authors:  Xin Yu Yang; Kai Di Zheng; Ke Lin; Guifeng Zheng; Hai Zou; Jian Min Wang; Yao Yao Lin; Chifundo Martha Chuka; Ren Shan Ge; Weitao Zhai; Jian Guang Wang
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  KIAA1199 as a potential diagnostic biomarker of rheumatoid arthritis related to angiogenesis.

Authors:  Xinyu Yang; Pengcheng Qiu; Bingbing Chen; Yaoyao Lin; Zhonghao Zhou; Renshan Ge; Hai Zou; Jianmin Wang; Jianguang Wang
Journal:  Arthritis Res Ther       Date:  2015-05-29       Impact factor: 5.156

8.  Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

Authors:  J Bluett; I Ibrahim; D Plant; K L Hyrich; A W Morgan; A G Wilson; J D Isaacs; A Barton
Journal:  Pharmacogenomics J       Date:  2013-07-16       Impact factor: 3.550

9.  Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Yukiko Nozawa; Hiroe Sato; Takeshi Nakatsue; Daisuke Kobayashi; Yoko Wada; Takako Saeki; Masaaki Nakano; Ichiei Narita
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

10.  The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis.

Authors:  Siyu Tao; Xue Wang; Chenxi Liao; Yan Xiong; Jie Tang; Nannan Jiang; Yuan Li; Xinyue Hu; Rouxian Shuai; Yueyue Wang; Ping Wu
Journal:  Pain Res Manag       Date:  2021-10-13       Impact factor: 3.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.